InflammationPhase 1NCT02229201
Comparison of Two Anaesthetics on Brain During Brain Tumour Surgery
A Phase 1 study testing Propofol and Sevoflurane in people with Inflammation, run by University Medical Centre Ljubljana at 1 site in Slovenia.
Trial summary
Anaesthesia and surgical stress during craniotomy can lead to brain damage and activation of inflammatory response. Consequently inflammatory cytokines (IL6, IL8, IL10) are released. Cell mediated immune balance can increase postoperative complications (infections, wound healing, multiple organ dysfunction). Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Inflammation
- What is being tested?
- Propofol and Sevoflurane
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteSlovenia
- Study dates
- May 2010to Dec 2013
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 18-80 years
- American Society of Anaesthesiologists (ASA) physical status I-III
- Scheduled for brain tumour surgery
- Glasgow Coma Score 15
- Cooperative
Who cannot join
- No written informed consent
- Eendocrine systematic disease
- Ddrugs that alter endocrine metabolism
- History of drug hypersensitivity
- Drug addiction
- Perioperative blood derivatives.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase 1 Study of the Impact of Propofol vs. Sevoflurane on Brain Damage and Inflammatory Response During Brain Tumour Surgery
Anaesthesia and surgical stress during craniotomy can lead to brain damage and activation of inflammatory response. Consequently inflammatory cytokines (IL6, IL8, IL10) are released. Cell mediated immune balance can increase postoperative complications (infections, wound healing, multiple organ dysfunction). Many studies have shown that volatile anaesthetics reduce systemic and local inflammatory response during major surgery, but animal studies have shown that volatile anaesthetics can induce neuroinflammation (IL6, NF-κB) that leads to decline of cognitive function in rodent and possible human.
Our aim was to investigate how anaesthetic technique for craniotomy influences the release of inflammatory cytokines. Our hypothesis was that when optimal neuroprotective strategies are followed during surgery intravenous anaesthesia attenuates inflammatory response comparing to inhalational anaesthesia.
Read more
The investigators included 40 patients anaesthetised with remifentanil based anaesthesia with sevoflurane (S group) or propofol (P group).
Plasma levels of IL6, IL8, IL10 were measured during preoperative, perioperative and postoperative periods of both groups of patients. The investigators also noted emergence parameters, postoperative (pain, shivering, vomiting) and neurological complications after surgery.
Read the detailed description
Anaesthetic technique for craniotomy has to provide optimal cerebral perfusion, oxygenation and prevent brain oedema (1). It also has to lower the stress response on pain during intubation and surgical manipulation. Emergence from anaesthesia has to be rapid and smooth to permit early postoperative neurological evaluation. The most likely opioid in the last decade is short acting opioid remifentanil that can be easy titrated during the procedure and provides early recovery (2, 3, 4, 5). Currently the propofol-remifentanil and sevoflurane-remifentanil are the most frequently used combinations for craniotomy (6, 7). Recently a multicentre study was published that did not show differences in early recovery between three groups (propofol-remifentanil: TIVA, sevoflurane-remifentanil, sevoflurane-fentanyl). Either technique provided optimal surgical conditions. The group received TIVA had attenuated changes in stress biomarkers (cortizol in plasma and urine, cateholamines. (8).
Anaesthesia and surgical stress during craniotomy can lead to brain damage and activation of inflammatory response (9, 10). Consequently inflammatory cytokines (IL6, IL8, IL10) are released. Cell mediated immune balance can increase postoperative complications (infections, wound healing, multiple organ dysfunction). Many studies have shown that volatile anaesthetics reduce systemic and local inflammatory response during major surgery (11, 12, 13, 14), but animal studies have shown that volatile anaesthetics can induce neuroinflammation (IL6, NF-κB) that leads to decline of cognitive function in rodent and possible human (15,16).
Our aim was to investigate how anaesthetic technique for craniotomy influences the release of inflammatory cytokines. Our hypothesis was that when optimal neuroprotective strategies are followed during surgery intravenous anaesthesia attenuates inflammatory response comparing to inhalational anaesthesia.
Plasma levels of IL6, IL8, IL10 were measured during preoperative, perioperative and postoperative periods of both groups of patients. The investigators also noted emergence parameters, postoperative (pain, shivering, vomiting) and neurological complications after surgery.
Patients and methods
Anaesthesia regimen:
On arrival in the operating room, the patients were randomly assigned to either Group P or Group S. Randomisation was done according to computer-generated order.
All patients were on a regimen of dexamethasone 4x4mg/day with the first dose given at least one day before surgery.
After arriving to the operating room the standard monitoring was instituted. An arterial catheter was placed in the radial artery to continuously monitor blood pressure. For extended haemodynamic monitoring Vigileo system was used.
Patients were premedicated with midazolam (2-3 mg i.v.) and ondansetron (4-8 mg i.v.). Antibiotic prophylaxis with intravenous cefazolin 2g/100 ml 0.9% NaCl was invariably used in all patients.
Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories). Before intubation all patients received remifentanil (Ultiva, GlaxoSmithKline) and rocuronium (Esmeron, MSD).
After intubation, patient's lungs were ventilated mechanically, with 1:2 oxygen-air mixtures in P and S group. Ventilation was adjusted to maintain normocapnia. Anaesthesia was maintained by continuous infusion of propofol 4-6 mg/kg/h in the P group and with sevoflurane 0,8-1 MAC in the S group. Remifentanil was adjusted regarding to anaesthesia response (0.1 - 2 μg/kg/min). The depth of anaesthesia was measured by a bispectral index (BIS) monitor; BIS values were maintained at 40-60.
For haemodynamic management the following algorithm was used: continuous infusion of 0.9% NaCl 6 mL kg-¹ for the first hour, followed by 2.5 ml kg-¹h-¹ . If CI < 2 L/min/m2and SVV > 10%, 6% hydroxyethyl starch (Voluven, Fresenius Kabi) until SVV-10% ; if there is no improvement after 250 ml 6% HES-a, ephedrine (0.5% Efedrin, UMC Ljubljana Pharmacy) 5-10 mg iv or fenilefrin 50-100 μg (0.01%, UMC Ljubljana Pharmacy). If CI < 2 L/min/m2, SVV < 10% and heart beat < 40/min, atropine 0,5 mg. If the mean arterial pressure increases by more than 30% and the heart rate by more than 30% from baseline, the infusion of remifentanil is increased. Any adverse hemodynamic events that did not respond to changes in anaesthetic regimen could be managed with urapidil or metoprolol, as appropriate. Hypotension following blood losses was maintained with colloids (6% HAES) and blood replacement. Hemodynamic parameters were monitored continuously at 5-min intervals from the beginning of induction until the patients were discharged from the PACU.
30 minutes before the end of the surgery (at the time of dura closer) piritramid 5-10 mg was administered. Continuous intravenous infusion of piritramid was started postoperatively as patient control analgesia (PCA). The time of the operation was determined as the time from pin head-holder placement to its removal. The time from the end of the operation to the tracheal extubation was also noted. All patients were extubated in the operating theatre and then transferred to the recovery room.
Postoperative management:
After surgery, the patients stayed in the recovery room for one hour and were then transferred to the intensive care unit of the Department of Neurosurgery.
Standard postoperative monitoring generally used in these procedures was implemented. Oxygen titrated to the lowest level needed to achieve the target arterial oxygen saturation of 96%, was administered via a Venturi mask. Post anaesthetic adverse events and medication in ICU were recorded for a period of 24 h after anaesthesia. Adverse events were defined as any unintended changes in body function or well being, such as hypertension, postoperative nausea and vomiting, pain, neurological complications, in particular if clinical intervention or drug therapy was required.
Hospital stay was also recorded.
Study design:
This prospective randomised single centre study was conducted at the Department of Anaesthesiology and Surgical Intensive Care and at the Department of Neurosurgery, in close cooperation with the Department of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana. The investigators included 40 patients anaesthetised with remifentanil based anaesthesia with sevoflurane (S group) or propofol (P group). The study was approved by the National Medical Ethics Committee of the Republic of Slovenia. All the procedures were performed in accordance with Helsinki declaration. The written informed concern was obtained from all included patients. The patients included in the study were given anaesthesia by the same anaesthesiologist.
The data recorded included demographic characteristics, time of surgery, time to extubation, hemodynamic parameters.
Arterial blood samples for the determinations of cytokines (IL 6, IL 8, IL 10) were drawn at the following time points: 1. before induction, 2. During tumor resection 3. at the end of the surgery, and 4. 24 hours after surgery 5. 48 hours after surgery.
For analyses of serum interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10), blood samples were collected in tubes without additive. After centrifugation serum samples were stored at -20 ºC until analysis. Analyses of samples were performed in one batch. Chemiluminescent immunometric assay (Immulite analyzer; Siemens Healthcare, Erlangen, Germany) was used to measure the concentrations of IL-6, IL-8, and IL-10.
- Conditions
- Inflammation
- Being tested
- Propofol, Sevoflurane
- Keywords
- propofol, sevoflurane, Interleukin 6, Interleukin 10
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PropofolDrug
Also called Propoven 1%
4-6 mg/kg/h during anaesthesia
SevofluraneDrug
Also called Sevorane
0.8 MAC
| Study group | Role | What they receive |
|---|---|---|
| Propofol | Experimental | intravenous anaesthetic Receives: Drug: Propofol |
| Sevoflurane | Active comparator | volatile anaesthetic Receives: Drug: Sevoflurane |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interleukin 10 plasma concentrations
The interleukin 10 plasma concentrations during craniotomy (preoperative, perioperative and postoperative periods)
Measured: Within 48 hours (1. Before surgery and anaesthesia 2. During surgery, 3. At the end of surgery 4.First postoperative day 5.Second postoperative day)
Secondary outcomes (9)
Hospital stay
Measured: within the first 15 days after surgery
Pulmonary complications
Measured: within the first 15 days after surgery
Cardiovascular complications
Measured: within the first 15 days after surgery
Neurological complications
Measured: within the first 15 days after surgery
Reoperation
Measured: within the first 15 days after surgery
Death
Measured: within the first 15 days after surgery
Postoperative nausea and vomiting (PONV)
Post anaesthetic adverse events and medication in ICU were recorded for a period of 24 h after anaesthesia. Adverse events were defined as any unintended changes in body function or well being.
Measured: within the first 24 hours after surgery
Pain using VAS score
Post anaesthetic adverse events and medication in ICU were recorded for a period of 24 h after anaesthesia. Adverse events were defined as any unintended changes in body function or well being, in particular if clinical intervention or drug therapy was required.
Measured: within the first 24 hours after surgery
Change of blood pressure from the baseline
Post anaesthetic adverse events and medication in ICU were recorded for a period of 24 h after anaesthesia. Adverse events were defined as any unintended changes in body function or well being, in particular if clinical intervention or drug therapy was required.
Measured: within the first 24 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2014 (estimated)
- Study startMay 2010
- Primary completionDec 2013
- Study completionDec 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for InflammationStudies of the same condition, open and under way.
- More trials run by University Medical Centre LjubljanaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jasmina Markovic Bozic, University Medical Centre Ljubljana
- Investigators
- Jasmina Markovic Bozic, MD, MSC, Principal investigator, CD of Anaesthesiology and Intensive Therapy, University Medical Centre LjubljanBlaz Karpe, PHD, Principal investigator, Faculty of Natural Science and Engineering, University of LjubljanaIztok Potocnik, MD, MSC, Principal investigator, CD of Anaesthesiology and Intensive Therapy, University Medical Centre LjubljanAles Jerin, PHD, Principal investigator, CLINICAL INSTITUTE OF CLINICAL CHEMISTRY AND BIOCHEMISTRY, University Medical Centre LjubljanaAndrej Vranič, MD, PHD, Principal investigator, CD of Neurosurgery, University Medical Centre LjubljanaVesna Novak Jankovic, PROF, PHD, Study chair, CD of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02229201
- Sponsor's protocol ID
- UMCL-NKG-01
- Status last verified
- Aug 2014
- First submitted
- 11 Aug 2014
- Last updated
- 1 Sep 2014
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Blum FE, Zuo Z. Volatile anesthetics-induced neuroinflammatory and anti-inflammatory responses. Med Gas Res. 2013 Aug 1;3(1):16. doi: 10.1186/2045-9912-3-16.
PubMed 23915963El Beheiry H. Protecting the brain during neurosurgical procedures: strategies that can work. Curr Opin Anaesthesiol. 2012 Oct;25(5):548-55. doi: 10.1097/ACO.0b013e3283579622.
PubMed 22895122Markovic-Bozic J, Karpe B, Potocnik I, Jerin A, Vranic A, Novak-Jankovic V. Effect of propofol and sevoflurane on the inflammatory response of patients undergoing craniotomy. BMC Anesthesiol. 2016 Mar 22;16:18. doi: 10.1186/s12871-016-0182-5.
PubMed 27001425
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1 Study of the Impact of Propofol vs. Sevoflurane on Brain Damage and Inflammatory Response During Brain Tumour Surgery
- ClinicalTrials.gov ID
- NCT02229201
- Acronym / sponsor ID
- UMCL-NKG-01
- Conditions
- Inflammation
- Keywords
- propofol, sevoflurane, Interleukin 6, Interleukin 10
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- May 2010
- Primary completion
- Dec 2013 (actual)
- Study completion
- Dec 2013 (actual)
- First posted
- 1 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Anaesthesia and surgical stress during craniotomy can lead to brain damage and activation of inflammatory response. Consequently inflammatory cytokines (IL6, IL8, IL10) are released. Cell mediated immune balance can increase postoperative complications (infections, wound healing, multiple organ dysfunction). Many studies have shown that volatile anaesthetics reduce systemic and local inflammatory response during major surgery, but animal studies have shown that volatile anaesthetics can induce neuroinflammation (IL6, NF-κB) that leads to decline of cognitive function in rodent and possible human.
Our aim was to investigate how anaesthetic technique for craniotomy influences the release of inflammatory cytokines. Our hypothesis was that when optimal neuroprotective strategies are followed during surgery intravenous anaesthesia attenuates inflammatory response comparing to inhalational anaesthesia.
The investigators included 40 patients anaesthetised with remifentanil based anaesthesia with sevoflurane (S group) or propofol (P group).
Plasma levels of IL6, IL8, IL10 were measured during preoperative, perioperative and postoperative periods of both groups of patients. The investigators also noted emergence parameters, postoperative (pain, shivering, vomiting) and neurological complications after surgery.
Detailed description
Anaesthetic technique for craniotomy has to provide optimal cerebral perfusion, oxygenation and prevent brain oedema (1). It also has to lower the stress response on pain during intubation and surgical manipulation. Emergence from anaesthesia has to be rapid and smooth to permit early postoperative neurological evaluation. The most likely opioid in the last decade is short acting opioid remifentanil that can be easy titrated during the procedure and provides early recovery (2, 3, 4, 5). Currently the propofol-remifentanil and sevoflurane-remifentanil are the most frequently used combinations for craniotomy (6, 7). Recently a multicentre study was published that did not show differences in early recovery between three groups (propofol-remifentanil: TIVA, sevoflurane-remifentanil, sevoflurane-fentanyl). Either technique provided optimal surgical conditions. The group received TIVA had attenuated changes in stress biomarkers (cortizol in plasma and urine, cateholamines. (8).
Anaesthesia and surgical stress during craniotomy can lead to brain damage and activation of inflammatory response (9, 10). Consequently inflammatory cytokines (IL6, IL8, IL10) are released. Cell mediated immune balance can increase postoperative complications (infections, wound healing, multiple organ dysfunction). Many studies have shown that volatile anaesthetics reduce systemic and local inflammatory response during major surgery (11, 12, 13, 14), but animal studies have shown that volatile anaesthetics can induce neuroinflammation (IL6, NF-κB) that leads to decline of cognitive function in rodent and possible human (15,16).
Our aim was to investigate how anaesthetic technique for craniotomy influences the release of inflammatory cytokines. Our hypothesis was that when optimal neuroprotective strategies are followed during surgery intravenous anaesthesia attenuates inflammatory response comparing to inhalational anaesthesia.
Plasma levels of IL6, IL8, IL10 were measured during preoperative, perioperative and postoperative periods of both groups of patients. The investigators also noted emergence parameters, postoperative (pain, shivering, vomiting) and neurological complications after surgery.
Patients and methods
Anaesthesia regimen:
On arrival in the operating room, the patients were randomly assigned to either Group P or Group S. Randomisation was done according to computer-generated order.
All patients were on a regimen of dexamethasone 4x4mg/day with the first dose given at least one day before surgery.
After arriving to the operating room the standard monitoring was instituted. An arterial catheter was placed in the radial artery to continuously monitor blood pressure. For extended haemodynamic monitoring Vigileo system was used.
Patients were premedicated with midazolam (2-3 mg i.v.) and ondansetron (4-8 mg i.v.). Antibiotic prophylaxis with intravenous cefazolin 2g/100 ml 0.9% NaCl was invariably used in all patients.
Anaesthesia induction in Group P was performed with propofol (Propoven, Fresenius Kabi) and in Group S with sevoflurane (Sevorane, Abbott Laboratories). Before intubation all patients received remifentanil (Ultiva, GlaxoSmithKline) and rocuronium (Esmeron, MSD).
After intubation, patient's lungs were ventilated mechanically, with 1:2 oxygen-air mixtures in P and S group. Ventilation was adjusted to maintain normocapnia. Anaesthesia was maintained by continuous infusion of propofol 4-6 mg/kg/h in the P group and with sevoflurane 0,8-1 MAC in the S group. Remifentanil was adjusted regarding to anaesthesia response (0.1 - 2 μg/kg/min). The depth of anaesthesia was measured by a bispectral index (BIS) monitor; BIS values were maintained at 40-60.
For haemodynamic management the following algorithm was used: continuous infusion of 0.9% NaCl 6 mL kg-¹ for the first hour, followed by 2.5 ml kg-¹h-¹ . If CI < 2 L/min/m2and SVV > 10%, 6% hydroxyethyl starch (Voluven, Fresenius Kabi) until SVV-10% ; if there is no improvement after 250 ml 6% HES-a, ephedrine (0.5% Efedrin, UMC Ljubljana Pharmacy) 5-10 mg iv or fenilefrin 50-100 μg (0.01%, UMC Ljubljana Pharmacy). If CI < 2 L/min/m2, SVV < 10% and heart beat < 40/min, atropine 0,5 mg. If the mean arterial pressure increases by more than 30% and the heart rate by more than 30% from baseline, the infusion of remifentanil is increased. Any adverse hemodynamic events that did not respond to changes in anaesthetic regimen could be managed with urapidil or metoprolol, as appropriate. Hypotension following blood losses was maintained with colloids (6% HAES) and blood replacement. Hemodynamic parameters were monitored continuously at 5-min intervals from the beginning of induction until the patients were discharged from the PACU.
30 minutes before the end of the surgery (at the time of dura closer) piritramid 5-10 mg was administered. Continuous intravenous infusion of piritramid was started postoperatively as patient control analgesia (PCA). The time of the operation was determined as the time from pin head-holder placement to its removal. The time from the end of the operation to the tracheal extubation was also noted. All patients were extubated in the operating theatre and then transferred to the recovery room.
Postoperative management:
After surgery, the patients stayed in the recovery room for one hour and were then transferred to the intensive care unit of the Department of Neurosurgery.
Standard postoperative monitoring generally used in these procedures was implemented. Oxygen titrated to the lowest level needed to achieve the target arterial oxygen saturation of 96%, was administered via a Venturi mask. Post anaesthetic adverse events and medication in ICU were recorded for a period of 24 h after anaesthesia. Adverse events were defined as any unintended changes in body function or well being, such as hypertension, postoperative nausea and vomiting, pain, neurological complications, in particular if clinical intervention or drug therapy was required.
Hospital stay was also recorded.
Study design:
This prospective randomised single centre study was conducted at the Department of Anaesthesiology and Surgical Intensive Care and at the Department of Neurosurgery, in close cooperation with the Department of Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana. The investigators included 40 patients anaesthetised with remifentanil based anaesthesia with sevoflurane (S group) or propofol (P group). The study was approved by the National Medical Ethics Committee of the Republic of Slovenia. All the procedures were performed in accordance with Helsinki declaration. The written informed concern was obtained from all included patients. The patients included in the study were given anaesthesia by the same anaesthesiologist.
The data recorded included demographic characteristics, time of surgery, time to extubation, hemodynamic parameters.
Arterial blood samples for the determinations of cytokines (IL 6, IL 8, IL 10) were drawn at the following time points: 1. before induction, 2. During tumor resection 3. at the end of the surgery, and 4. 24 hours after surgery 5. 48 hours after surgery.
For analyses of serum interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10), blood samples were collected in tubes without additive. After centrifugation serum samples were stored at -20 ºC until analysis. Analyses of samples were performed in one batch. Chemiluminescent immunometric assay (Immulite analyzer; Siemens Healthcare, Erlangen, Germany) was used to measure the concentrations of IL-6, IL-8, and IL-10.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Propofol | Experimental | Drug: Propofolintravenous anaesthetic |
| Sevoflurane | Active comparator | Drug: Sevofluranevolatile anaesthetic |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- age 18-80 years
- American Society of Anaesthesiologists (ASA) physical status I-III
- Scheduled for brain tumour surgery
- Glasgow Coma Score 15
- Cooperative
Key exclusion criteria (6 listed)
- No written informed consent
- Eendocrine systematic disease
- Ddrugs that alter endocrine metabolism
- History of drug hypersensitivity
- Drug addiction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PropofolAlso: Propoven 1%4-6 mg/kg/h during anaesthesia | Drug | Propofol |
| SevofluraneAlso: Sevorane0.8 MAC | Drug | Sevoflurane |
Primary outcome
Interleukin 10 plasma concentrations
Time frame: Within 48 hours (1. Before surgery and anaesthesia 2. During surgery, 3. At the end of surgery 4.First postoperative day 5.Second postoperative day)
The interleukin 10 plasma concentrations during craniotomy (preoperative, perioperative and postoperative periods)
9 secondary outcomes
Hospital stay
Time frame: within the first 15 days after surgery
Pulmonary complications
Time frame: within the first 15 days after surgery
Cardiovascular complications
Time frame: within the first 15 days after surgery
Neurological complications
Time frame: within the first 15 days after surgery
Reoperation
Time frame: within the first 15 days after surgery
Death
Time frame: within the first 15 days after surgery
Postoperative nausea and vomiting (PONV)
Time frame: within the first 24 hours after surgery
Pain using VAS score
Time frame: within the first 24 hours after surgery
Change of blood pressure from the baseline
Time frame: within the first 24 hours after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2014.
- Background: PubMed 23915963Blum FE, Zuo Z. Volatile anesthetics-induced neuroinflammatory and anti-inflammatory responses. Med Gas Res. 2013 Aug 1;3(1):16. doi: 10.1186/2045-9912-3-16.
- Background: PubMed 22895122El Beheiry H. Protecting the brain during neurosurgical procedures: strategies that can work. Curr Opin Anaesthesiol. 2012 Oct;25(5):548-55. doi: 10.1097/ACO.0b013e3283579622.
- Derived from this study: PubMed 27001425Markovic-Bozic J, Karpe B, Potocnik I, Jerin A, Vranic A, Novak-Jankovic V. Effect of propofol and sevoflurane on the inflammatory response of patients undergoing craniotomy. BMC Anesthesiol. 2016 Mar 22;16:18. doi: 10.1186/s12871-016-0182-5.
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jasmina Markovic Bozic, MD, MSC principal investigator
CD of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljan
Blaz Karpe, PHD principal investigator
Faculty of Natural Science and Engineering, University of Ljubljana
Iztok Potocnik, MD, MSC principal investigator
CD of Anaesthesiology and Intensive Therapy, University Medical Centre Ljubljan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Propofol and Sevoflurane in people with Inflammation, run by University Medical Centre Ljubljana at 1 site in Slovenia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interleukin 10 plasma concentrations (time frame: Within 48 hours (1. Before surgery and anaesthesia 2. During surgery, 3. At the end of surgery 4.First postoperative day 5.Second postoperative day)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02229201, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2014.